Advertisement

International Urogynecology Journal

, Volume 29, Issue 7, pp 1051–1060 | Cite as

The effect of solifenacin on postvoid dribbling in women: results of a randomized, double-blind placebo-controlled trial

  • Tova Ablove
  • Lauren N. Bell
  • Hong Liang
  • Richard J. Chappell
  • Hale Z. Toklu
  • Steven H. Yale
Original Article

Abstract

Introduction and hypothesis

To determine the effectiveness of the muscarinic receptor antagonist solifenacin (VESIcare®) in the treatment of postvoid dribbling (PVD).

Methods

We carried out a multicenter, 12-week, double-blind, randomized, placebo-controlled, parallel design study. Between 2012 and 2015, a total of 118 women (age 18–89 years) with PVD at least twice/weekly, were randomized to receive solifenacin (5 mg; n = 58) or placebo (n = 60) once daily. The primary outcome was the percentage reduction in PVD episodes. Secondary outcomes included the percentage of patients with ≥50% reduction in PVD episodes and changes in quality of life.

Results

There were no differences in either the primary or secondary outcome variables. Subgroup analysis, based on those with more severe disease (>10 PVD episodes/week), showed a greater and significant percentage reduction in the frequency of PVD episodes per day (60.3% vs 32.1%; p = 0.035) and a higher percentage of patients showing ≥50% reduction in the frequency of PVD episodes with solifenacin (68.1% vs 45.8%; p = 0.0476). A significant solifenacin effect occurred at week 2 and continued through week 12 for the subgroup. For solifenacin, PVD reduction was the same for the entire cohort and subgroup, whereas for placebo, it was 10% lower in the subgroup, declining from 42% to 32%.

Conclusion

There were no differences in PVD outcomes between the solifenacin and placebo groups. Solifenacin may play a role in treating women with the most severe symptoms. Because of the powerful placebo response seen in this study, behavior-based interventions may be useful for treating PVD.

Keywords

Postmicturition dribbling Randomized controlled trial Urinary incontinence VESIcare® Muscarinic antagonists Anticholinergic 

Abbreviations

LUTS

Lower urinary tract symptoms

NO

Nitric oxide

OVB

Overactive bladder

PVD

Postvoid dribbling

Notes

Acknowledgements

The authors would like to acknowledge the University of Wisconsin Madison and Marshfield Clinic Institute for Clinical and Translational Research and the Wisconsin Network for Health Research for assistance with data collection.

Funding

Financial support (and/or study drug) for this study was provided by Astellas Pharma.

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc. 1998;46(4):473–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Temml C, Haidinger G, Schmidbauer J, Schatzl G, Madersbacher S. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn. 2000;19(3):259–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Jeffery ST, Doumouchtsis SK, Vlachos IS, Fynes MM. Are voiding symptoms really associated with abnormal urodynamic voiding parameters in women? Int J Urol. 2008;15(12):1044–8.  https://doi.org/10.1111/j.1442-2042.2008.02180.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Ablove T. Post void dribbling: incidence and risk factors. Neurourol Urodyn. 2010;29(3):432–6.  https://doi.org/10.1002/nau.20775.PubMedCrossRefGoogle Scholar
  6. 6.
    El-Nashar SA, Bacon MM, Kim-Fine S, Weaver AL, Gebhart JB, Klingele CJ. Incidence of female urethral diverticulum: a population-based analysis and literature review. Int Urogynecol J. 2014;25(1):73–9.  https://doi.org/10.1007/s00192-013-2155-2.CrossRefPubMedGoogle Scholar
  7. 7.
    Rasmussen JSS, Ablove T. A survey on the effect of anticholinergic therapy on post-void dribbling. UroToday Int J. 2012;5(3):art14.  https://doi.org/10.3834/uij.1944-5784.2012.06.01.CrossRefGoogle Scholar
  8. 8.
    Cardozo L, Hessdorfer E, Milani R, Arano P, Dewilde L, Slack M, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008;102(9):1120–7.  https://doi.org/10.1111/j.1464-410X.2008.07939.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84(3):935–86.  https://doi.org/10.1152/physrev.00038.2003.CrossRefPubMedGoogle Scholar
  10. 10.
    Orman B, Sterin-Borda L, Reina S, Borda ES. Neuronal nitric oxide synthase activity in rat urinary bladder detrusor: participation in M3 and M4 muscarinic receptor function. Auton Autacoid Pharmacol. 2005;25(3):93–100.  https://doi.org/10.1111/j.1474-8673.2005.00337.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Birder LA, Apodaca G, De Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Phys. 1998;275(2 Pt 2):F226–9.Google Scholar
  12. 12.
    Masuda H, Okuno T, Suzuki M, Kihara K, Goto M, Azuma H. Different distribution of nitric oxide synthase and soluble guanylyl cyclase activities in the detrusor and proximal urethra of the rabbit. J Urol. 2002;168(5):2286–90.  https://doi.org/10.1097/01.ju.0000031722.92653.16.CrossRefPubMedGoogle Scholar
  13. 13.
    Zygmunt PM, Zygmunt PK, Hogestatt ED, Andersson KE. Effects of omega-conotoxin on adrenergic, cholinergic and NANC neurotransmission in the rabbit urethra and detrusor. Br J Pharmacol. 1993;110(4):1285–90.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Braverman AS, Miller LS, Vegesna AK, Tiwana MI, Tallarida RJ, Ruggieri MR Sr. Quantitation of the contractile response mediated by two receptors: M2 and M3 muscarinic receptor-mediated contractions of human gastroesophageal smooth muscle. J Pharmacol Exp Ther. 2009;329(1):218–24.  https://doi.org/10.1124/jpet.108.148106.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Phys. 1998;275(5 Pt 2):R1654–60.Google Scholar
  16. 16.
    Restorick JM, Mundy AR. The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor. Br J Urol. 1989;63(1):32–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Basra R, Kelleher C. A review of solifenacin in the treatment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117–28.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Pharma A VESICARE® Product Monograph.Google Scholar
  19. 19.
    Van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol. 2006;50(3):440–52; discussion 453.  https://doi.org/10.1016/j.eururo.2006.05.014.CrossRefPubMedGoogle Scholar
  20. 20.
    De la Fuente-Fernandez R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol. 2002;1(2):85–91.CrossRefPubMedGoogle Scholar
  21. 21.
    Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–66.  https://doi.org/10.1038/nrn2401.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Abrams P. Managing lower urinary tract symptoms in older men. BMJ. 1995;310(6987):1113–7.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Resnick NM. Improving treatment of urinary incontinence. JAMA. 1998;280(23):2034–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Yalcin I, Bump RC. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. Am J Obstet Gynecol. 2004;191(1):194–7.  https://doi.org/10.1016/j.ajog.2004.03.089.CrossRefPubMedGoogle Scholar
  25. 25.
    Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3(3):237–47.CrossRefPubMedGoogle Scholar
  27. 27.
    De Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen JG, Kleijnen J. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol. 1999;48(6):853–60.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology. 1997;112(6):1854–8.CrossRefPubMedGoogle Scholar

Copyright information

© The International Urogynecological Association 2018

Authors and Affiliations

  • Tova Ablove
    • 1
    • 2
    • 3
  • Lauren N. Bell
    • 4
  • Hong Liang
    • 4
    • 5
  • Richard J. Chappell
    • 6
  • Hale Z. Toklu
    • 4
    • 5
  • Steven H. Yale
    • 4
    • 5
  1. 1.Department of Obstetrics and GynecologyUniversity of WisconsinMadisonUSA
  2. 2.Department of Obstetrics and GynecologyUniversity at BuffaloBuffaloUSA
  3. 3.Department of Obstetrics and GynecologyConventusBuffaloUSA
  4. 4.University of Central Florida College of MedicineOrlandoUSA
  5. 5.Departments of Medicine and Graduate Medical EducationNorth Florida Regional Medical CenterGainesvilleUSA
  6. 6.Department of Biostatistics and Medical InformaticsUniversity of WisconsinMadisonUSA

Personalised recommendations